Fig. 1 · Structure

Documents & Downloads

Geldanamycin

Cat. No. A11025 CAS 30562-34-6

Hsp90 inhibitor

Geldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 μM) and inhibits its chaperone activity.

In Stock

Publications for Geldanamycin

2 publications citing this product

  1. Sunayn Cheku, .et al. , Fly (Austin), 2025, Apr 25;19(1):2497565 PMID: 40277072
  2. Michael Heider, .et al. , Mol Cell, 2021, Mar 18;81(6):1170-1186 PMID: 33571422

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Geldanamycin inhibits Hsp90 ATPase activity. In a purified yeast Hsp90 assay, the reported IC50 was 3–5 μM; approximately 10% of total ATPase activity remained geldanamycin insensitive. This biochemical endpoint is distinct from cellular viability potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p185 70 nM
HSP90 (N-terminal domain) Kd 0.78 μM
HSP90 Kd 1.2 μM

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 0.07 μM Antiproliferative activity against human A2780 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27476419]
A-375 IC50 0.06 μM Antiproliferative activity against human A375 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27476419]
A-431 IC50 0.2 μM Antiproliferative activity against human A431 cells after 72 hrs [PMID: 20655237]
A-431 IC50 40 nM Cytotoxicity against human A431 cells after 72 hrs by MTT assay [PMID: 25277067]
A549 IC50 0.1 μM Antiproliferative activity against human A549 cells after 72 hrs by SRB assay [PMID: 29172085]
A549 IC50 0.109 μM Anticancer activity against human A549 cells measured after 72 hrs by SRB assay [PMID: 27283788]
A549 IC50 0.15 μM Cytotoxicity against human A549 cells after 2 days by AlamarBlue assay [PMID: 23947794]
A549 IC50 0.99 μM Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay [PMID: 32663707]
A549 IC50 97 nM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 25277067]
BGC-823 IC50 0.11 μM Antiproliferative activity against human BGC823 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27476419]
BGC-823 IC50 40 nM Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay [PMID: 25277067]
CAKI-1 IC50 0.056 μM Anticancer activity against human Caki1 cells measured after 72 hrs by SRB assay [PMID: 27283788]
CNE2Z IC50 0.31 μM Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay [PMID: 32527461]
HCT-116 EC50 0.03 μM Antiproliferative activity against human HCT116 cells measured on day 4 by Cell titer-glo assay [PMID: 21420297]
HCT-116 EC50 0.03 μM Antiproliferative activity against human HCT116 cells by luminescence assay [PMID: 21605975]
HCT-116 IC50 0.1 μM Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27476419]
HCT-116 IC50 0.15 μM Anticancer activity against human HCT116 cells measured after 72 hrs by SRB assay [PMID: 27283788]
HeLa IC50 > 5 μM Cytotoxicity against human HeLa cells at 72 hrs by MTS assay [PMID: 22162786]
HeLa IC50 0.06 μM Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay [PMID: 27266997]
HeLa IC50 798 nM Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 25277067]

20 records · Scroll to view more

Geldanamycin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Geldanamycin from 2 published references.

Geldanamycin In Vitro Studies

In a 48-hour MTT assay, geldanamycin had reported IC50 values of 12–140 nM across five mesothelioma cell lines. The non-cancerous NIH3T3 fibroblast IC50 was 59 nM, limiting claims of cancer-selective activity. [2]

Inhibition of purified yeast Hsp90 ATPase

Biochemical assay · Purified Saccharomyces cerevisiae Hsp82; coupled pyruvate kinase/lactate dehydrogenase ATPase assay at 37°C [1]

Geldanamycin inhibited ATP hydrolysis by purified yeast Hsp90. The authors reported an assay IC50 of 3–5 μM. About 10% residual ATPase activity was geldanamycin insensitive. Controls assessed both DMSO and interference with the coupled detection enzymes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of yeast Hsp90 ATPase activityIC50 3–5 μM[1]
Geldanamycin-insensitive residual ATPase activity in yeast Hsp90 preparationresidual activity 10% of total activity[1]

Literature-Reported Treatment Conditions

Treatment concentration
1.5, 9, 15 and 30 μM geldanamycin; 0.8 mM ATP in the assay
Method
Addition to purified protein in a regenerating coupled enzyme assay; NADH absorbance monitored at 340 nm, 37°C.
Vehicle
Geldanamycin dissolved in DMSO; 1% DMSO tested alone as a control.
Reported limits
Assay observation duration and replicate count are not specified in the selected assay methods or Figure 2 caption.
Methods and source locations

Compound reported in the paper: Geldanamycin; Compound label in the paper: geldanamycin

Results apply to the named parent compound and reported experimental material; they do not validate an Adooq lot or establish equivalent activity for derivatives.

Figure 2 and caption, p. 4830; Results: In vitro ATPase activity of Hsp90; Materials and methods: ATPase assay

Inhibition of yeast Hsp90 ATPase activity: Regenerating PK/LDH-coupled assay at 37°C, 0.8 mM ATP; reported range in Figure 2 caption, not a value fitted from the image. — Figure 2 and caption, p. 4830; Results: In vitro ATPase activity of Hsp90; Materials and methods: ATPase assay

Geldanamycin-insensitive residual ATPase activity in yeast Hsp90 preparation: Reported in Figure 2 caption. This residual limits any claim of complete inhibition of the preparation. — Figure 2 and caption, p. 4830; Results: In vitro ATPase activity of Hsp90; Materials and methods: ATPase assay

Cell viability across mesothelioma lines and non-cancerous fibroblasts

Cell-based study · Murine mesothelioma AB1 and AE17; human mesothelioma VGE62, MSTO-211H and JU77; non-cancerous murine NIH3T3 fibroblasts [2]

At 48 h, reported MTT IC50 values ranged from 12 to 140 nM in the five mesothelioma lines. NIH3T3 fibroblasts had an IC50 of 59 nM, so this panel does not establish cancer-selective inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AB1 murine mesothelioma relative cell viability after 48 hIC50 140 nM[2]
AE17 murine mesothelioma relative cell viability after 48 hIC50 30 nM[2]
NIH3T3 non-cancerous murine fibroblasts relative cell viability after 48 hIC50 59 nM[2]
VGE62 human mesothelioma relative cell viability after 48 hIC50 106 nM[2]
MSTO-211H human mesothelioma relative cell viability after 48 hIC50 114 nM[2]
JU77 human mesothelioma relative cell viability after 48 hIC50 12 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series indicated in Figure 2A–F; exact full MTT treatment series is not tabulated in the selected text and is not reconstructed from the plotted axis.
Exposure duration
48 h geldanamycin exposure before MTT viability assessment
Method
MTT assay in R10 medium; absorbance at 570 nm. Data normalized and fitted with log(geldanamycin) versus response.
Reported limits
Treatment stock solvent/final vehicle fraction and exact MTT dose series are not specified in the selected MTT section. DMSO added to dissolve MTT product is not treated as evidence for a drug-treatment vehicle. Figure caption gives 3 replicates without defining biological independence.
Methods and source locations

Compound reported in the paper: Geldanamycin; Compound label in the paper: geldanamycin

Results apply to the named parent compound and reported experimental material; they do not validate an Adooq lot or establish equivalent activity for derivatives.

Figure 2A–F and caption; Methods: MTT assay and Cell culture; Discussion: NIH3T3 non-cancer selectivity limitation

AB1 murine mesothelioma relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2A and caption; Methods: MTT assay

AE17 murine mesothelioma relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2B and caption; Methods: MTT assay

NIH3T3 non-cancerous murine fibroblasts relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2C and caption; Methods: MTT assay

VGE62 human mesothelioma relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2D and caption; Methods: MTT assay

MSTO-211H human mesothelioma relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2E and caption; Methods: MTT assay

JU77 human mesothelioma relative cell viability after 48 h: MTT assay, absorbance at 570 nm, normalized values fitted using log(geldanamycin) versus response; Figure 2 labels report IC50. Caption: means ± SD of 3 replicates; their independence is unspecified. — Figure 2F and caption; Methods: MTT assay

Geldanamycin In Vivo Studies

In mice bearing AB1-Luc mesothelioma, geldanamycin at 0.1 mg/kg intraperitoneally twice daily for five days produced no significant reduction in tumour bioluminescence versus vehicle. Tumour invasion remained evident histologically in both groups. The cellular results therefore did not translate into efficacy under this regimen. [2]

No significant efficacy in an AB1-Luc mesothelioma mouse model

Animal study · Female BALB/cJAusb mice, 10–12 weeks, bearing intraperitoneal AB1-Luc mesothelioma; vehicle-controlled experiment, n = 5 per group as shown in Figure 3 [2]

At 0.1 mg/kg twice daily on days 5–9, geldanamycin did not significantly reduce tumour bioluminescence or prevent histologically evident invasion. This is a negative result for this model and regimen; it does not establish absence of activity at every exposure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumour bioluminescence average radiance (photons/s/cm²/sr)between-group comparison Not statistically significant on days 7 and 10[2]
Mesothelioma invasion into surrounding organshistological observation Invasion present in vehicle and geldanamycin groups[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Twice daily, 8 hours apart
Treatment course
Days 5–9 after tumour inoculation; imaging days 4, 7 and 10; organ collection day 10
Vehicle
1% DMSO in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Geldanamycin 0.1 mg/kg
0.1 mg/kg per administration
Vehicle control group; Figure 3 caption n = 5 and plotted groups contain five mice each.No statistically significant reduction in tumour bioluminescence on days 7 or 10 relative to vehicle; histology showed invasion in both groups. The paper describes this dose as tolerable.[2]
Geldanamycin 0.1 mg/kg
Model: Female BALB/cJAusb mice, 10–12 weeks, with intraperitoneal AB1-Luc mesothelioma
Reported limits: Exact p values and effect confidence intervals are not given in Figure 3. No target-engagement or pharmacokinetic measurement is adopted.
Methods and source locations

Compound reported in the paper: Geldanamycin; Compound label in the paper: geldanamycin

Results apply to the named parent compound and reported experimental material; they do not validate an Adooq lot or establish equivalent activity for derivatives.

Figure 3A–E and caption; Results: Geldanamycin treatment does not have anti-mesothelioma activity in vivo; Methods: In vivo geldanamycin treatment and In vivo imaging system (IVIS)

Tumour bioluminescence average radiance (photons/s/cm²/sr): IVIS imaging; Figure 3D: mean ± SD, n = 5; unpaired t-test. Day 4 is pretreatment baseline. No exact p values read from the ns labels. — Figure 3A–E and caption; Results: Geldanamycin treatment does not have anti-mesothelioma activity in vivo; Methods: In vivo geldanamycin treatment and In vivo imaging system (IVIS)

Mesothelioma invasion into surrounding organs: Endpoint H&E sections, Figure 3E; scale bar = 100 μm; descriptive observation, not an equivalence test. — Figure 3A–E and caption; Results: Geldanamycin treatment does not have anti-mesothelioma activity in vivo; Methods: In vivo geldanamycin treatment and In vivo imaging system (IVIS)

Geldanamycin 0.1 mg/kg · Figure 3A–E and caption; Results: Geldanamycin treatment does not have anti-mesothelioma activity in vivo; Methods: In vivo geldanamycin treatment and In vivo imaging system (IVIS)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 30562-34-6
Applications Hsp90 inhibitor
Formula C29H40N2O9
Molecular Weight 560.6
SMILES
COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 32 mg/mL (57.08 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Geldanamycin Research References

  1. [1] Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo The EMBO journal (1998). PMID: 9707442 DOI: 10.1093/emboj/17.16.4829 Source material
  2. [2] Orozco Morales ML, Rinaldi CA, de Jong E, et al. Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma PloS one (2023). PMID: 37146029 DOI: 10.1371/journal.pone.0274364 Source material

Publications

2 publications citing this product

  1. Sunayn Cheku, .et al. , Fly (Austin), 2025, Apr 25;19(1):2497565 PMID: 40277072
  2. Michael Heider, .et al. , Mol Cell, 2021, Mar 18;81(6):1170-1186 PMID: 33571422

Added to your cart

View Cart Checkout
Loading...